Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to/who remain symptomatic despite H1 -antihistamine treatment, and has demonstrated good efficacy and safety in the clinical trial setting. Real-life clinical experience with omalizumab can be explored to address important practical questions relating to its use in CSU patients. Some experts have proposed that a consensus algorithm, covering various aspects to consider when using omalizumab in real-life clinical practice for the management of CSU, could answer many of these questions.
Department of Dermatology, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
A M
AM
Giménez-Arnau
Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Haifa, Israel.
E
E
Toubi
Salford Royal NHS Foundation Trust, Manchester Academic Health Science Center, University of Manchester, Manchester, UK.
A M
AM
Marsland
Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
M
M
Maurer
D000293:Adolescent; D000465:Algorithms; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D002648:Child; D002908:Chronic Disease; D006801:Humans; D000069444:Omalizumab / Q000627:therapeutic use*; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
D018926:Anti-Allergic Agents; D015415:Biomarkers; D000069444:Omalizumab